Compare 10X Genomics Inc (TXG) vs Vertiv Holdings Co (VRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Vertiv Holdings Co — how do they compare? 10X Genomics Inc trades at $79 (market cap $10.07B), while Vertiv Holdings Co trades at $247.76 (market cap $93.83B). The key difference: Vertiv Holdings Co is far larger — about 9.3× 10X Genomics Inc's market cap, and Vertiv Holdings Co pays a 0.1% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold 10X Genomics Inc for 92 Days and Vertiv Holdings Co for 39 Days on average.
| TXG | VRT | |
|---|---|---|
Market Cap | $10.07B | $93.83B |
Volume | 5,657,286 | 5,855,911 |
Sector | Health | Industrials |
52-Week High | $97.74 | $376.23 |
52-Week Low | $11.48 | $149.83 |
Typical Hold Time | 92 Days | 39 Days |
Enterprise Value | $9.59B | $94.06B |
Dividend Yield | — | 0.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.
TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.
Vertiv (VRT) trades at $246.49, down 2.63% on the day, as technical indicators show bearish momentum with the stock testing support near $242. Fundamentally, the company demonstrates strong profitability with 38% gross margins and 15% net income margins, while recent earnings have consistently beaten expectations. Revenue growth accelerated from $10.2B in 2025 to $11.5B projected for 2026, driven by AI data center demand.
The investment case balances strong analyst support (95% buy ratings with $364.94 price target) against elevated valuation multiples (P/E of 55) and recent legal scrutiny. While AI infrastructure tailwinds provide growth catalysts, the stock faces technical headwinds and needs to maintain its earnings beat streak to justify premium valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Vertiv Holdings Co
Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →
